CN103977187A - 一种治疗阳证疮疡的中药贴片的制备方法 - Google Patents
一种治疗阳证疮疡的中药贴片的制备方法 Download PDFInfo
- Publication number
- CN103977187A CN103977187A CN201410230329.7A CN201410230329A CN103977187A CN 103977187 A CN103977187 A CN 103977187A CN 201410230329 A CN201410230329 A CN 201410230329A CN 103977187 A CN103977187 A CN 103977187A
- Authority
- CN
- China
- Prior art keywords
- raw
- group
- pieces
- drug
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 11
- 208000025865 Ulcer Diseases 0.000 title description 2
- 231100000397 ulcer Toxicity 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 70
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 52
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 21
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 20
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 19
- 241000555712 Forsythia Species 0.000 claims description 19
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 19
- 229940116229 borneol Drugs 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- 235000005206 Hibiscus Nutrition 0.000 claims description 14
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 14
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims description 14
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 14
- 241000205571 Caulophyllum Species 0.000 claims description 12
- 239000002674 ointment Substances 0.000 claims description 12
- 241000213006 Angelica dahurica Species 0.000 claims description 10
- 239000008159 sesame oil Substances 0.000 claims description 10
- 235000011803 sesame oil Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- 235000019271 petrolatum Nutrition 0.000 claims description 5
- 238000002203 pretreatment Methods 0.000 claims description 5
- 229940099259 vaseline Drugs 0.000 claims description 5
- 241000206501 Actaea <angiosperm> Species 0.000 claims description 3
- 244000299790 Rheum rhabarbarum Species 0.000 claims 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 230000000694 effects Effects 0.000 description 31
- 238000012360 testing method Methods 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 19
- 230000008961 swelling Effects 0.000 description 17
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 241000219061 Rheum Species 0.000 description 12
- 206010015150 Erythema Diseases 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000012353 t test Methods 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 241000700198 Cavia Species 0.000 description 7
- 206010040914 Skin reaction Diseases 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000035483 skin reaction Effects 0.000 description 7
- 231100000430 skin reaction Toxicity 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000000548 hind-foot Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 4
- 241000125175 Angelica Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000014103 egg white Nutrition 0.000 description 4
- 210000000969 egg white Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 230000006996 mental state Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 229910052979 sodium sulfide Inorganic materials 0.000 description 4
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940063674 voltaren Drugs 0.000 description 4
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical group [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 206010051814 Eschar Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- 229930006703 (-)-borneol Natural products 0.000 description 1
- DTGKSKDOIYIVQL-QXFUBDJGSA-N (-)-borneol Chemical compound C1C[C@]2(C)[C@H](O)C[C@H]1C2(C)C DTGKSKDOIYIVQL-QXFUBDJGSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 244000168525 Croton tiglium Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- -1 coca Diols Chemical class 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000002828 disc diffusion antibiotic sensitivity testing Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000010729 leg swelling Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000001369 pituitary-adrenal system Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种治疗阳证疮疡的中药贴片的制备方法,包括药材的前处理,药材与凡士林、香油的混合等步骤,本发明制备的中药贴片疗效显著且低毒安全。
Description
技术领域
本发明涉及一种治疗阳证疮疡的中药贴片,属中医药技术领域。
背景技术
中医论治疮疡有阴阳之别,阳证疮疡“属六腑毒胜于外,其发暴而所患浮浅”,常因火热毒邪而发,导致局部营卫不和,经络阻塞,气血凝滞,多以局部红肿热痛为主症。目前,临床上治疗一般采用内服外敷的方法,其副作用较大,且疗效欠理想。
发明内容
为了解决上述技术问题,本发明提供了一种治疗阳证疮疡的中药贴片,其为外用制剂,疗效确切且低毒安全。
本发明的技术方案如下:一种治疗阳证疮疡的中药贴片,其特征在于,包括质量比为3:9:12的凡士林、香油、药粉;所述药粉由以下重量的药材制备而成:生芙蓉叶800-1200g、连翘800-1200g、生大黄800-1200g、生南星800-1200g、白芷800-1200g、升麻800-1200g、冰片40-60g。
制备方法如下:
(1)药物的前处理:处方药物均应为《中国药典》一部相应饮片下的处理方法处理,备用。
(2)生芙蓉叶、连翘、生大黄、生南星、白芷、升麻粉碎过6号筛,备用。
(3)将冰片加于香油中使其溶解,再加入上述药粉、凡士林及1%~6%的氮酮,充分混合制成棕褐色软膏,备用。
(4)将软膏摊涂于贴片上,即制备成治疗阳证疮疡的中药贴片。(可根据创面的大小,摊涂成不同的剂量,生药粉含量分别为:1.5g,3g, 6g。)
本发明中,贴片:山东圣纳医用制品有限公司,鲁食药监械(准)字2006第2640132。
本发明提供的中药贴片制剂是针对阳证疮疡而发明的,其药物组成是生芙蓉叶、连翘、生大黄、生南星、白芷、升麻、冰片,具有清热解毒,凉血活血,散结止痛之功。
方中生芙蓉叶辛平,凉血解毒,消肿止痛为君药,适用于痈疽肿毒,丹毒,烫伤,跌打损伤等症,可使初起者消肿止痛,或者脓聚毒出,为君药;连翘性苦微寒,清热解毒,消肿散结,有“疮家圣药”之称;生大黄苦寒气味重浊,具有清热解毒,活血祛瘀之效,外用可治疗痈疡肿毒、疔疮、烫伤等外科疮疡;生南星苦辛,辛而能散,决无有守之性,专主经络风痰,能散结消肿止痛,外可治疗瘰疠、痈肿、跃打损伤等;白芷性辛微温,功可祛风止痛,消肿排脓,共为臣药佐君清热解毒消肿;升麻,辛甘微寒取其辛散之性,使雍聚于皮肤的毒邪从皮而解;冰片辛苦,微寒,功能开窍醒神,清热止痛,二者为使药能够引毒透皮而解。
生芙蓉叶含延胡索酸及芦丁即芸香甙。经预试叶含黄酮甙、酚类、氨基酸、鞣质、还原糖等。现代药理研究表明具有抗炎作用,另外,芙蓉叶水煎剂对金黄色葡萄球菌、溶血性链球菌、绿脓杆菌有较强的抑制作用。
连翘对多种革兰阳性及阴性细菌均有抑制作用,其浓缩煎剂在体外可抑制伤寒杆菌、副伤寒杆菌、大肠杆菌、痢疾杆菌、白喉杆菌及霍乱弧菌、葡萄球菌、链球菌等。连翘在体外的抑菌作用与金银花大体相似;为银翘散中抗菌的主要成分。研究表明,连翘具有显著的抗炎作用,50%的连翘醇提取物水溶液 20ml/kg 腹腔注射,对大鼠巴豆油性肉芽囊有非常明显的抗渗出作用及降低炎灶微血管壁脆性作用.连翘能促进炎性屏障的形成,300%的连翘注射液30~40g/kg腹腔注射,对大鼠蛋清性脚肿有明显抑制作用;亦能促进对小鼠炎细胞的吞噬作用。
生大黄含有蒽类衍生物、苷类化合物、鞣质类、有机酸类、挥发油类等。治疗外科疮疡其药理研究表明主要作用表现在抗病原微生物作用,其抗菌有效成分为大黄酸、大黄素、芦荟大黄素等,主要影响叶酸的酶系统;抑制细菌核酸和蛋白质合成;抑制细菌生物氧化酶系统;诱生干扰素。另外还有抗炎、解热作用、抗衰老抗氧化作用。
生南星苦、辛,温,散结消肿,是外用治疗疮疡肿毒的常用药;现代药理研究表明主要有:
① 抗炎作用 对组织水肿、炎性渗出及毛细血管通透性增高均有抑制作用,并可通过提高垂体-肾上腺系统功能而间接发挥抗炎作用。
②镇静、镇痛,抗惊厥作用 天南星煎剂有明显的镇静、镇痛作用,并能明显延长戊巴比妥钠对小鼠催眠的作用;天南星的复方三生针镇静、镇痛作用明显,镇痛作用小于吗啡,但作用持久,并对戊巴比妥钠的催眠有协同作用。
白芷现代药理研究表明白芷在体外对大肠杆菌、宋氏和弗氏痢疾杆菌、变形杆菌、伤寒和副伤寒杆菌、绿脓杆菌、霍乱弧菌、某些革兰阳性细菌及人型结核杆菌等有不同程度的抑制作用;白芷煎剂、醚提取物和水提取物8g(生药)/kg灌胃,对小鼠醋酸扭体反应的抑制率分别为69.6%,52.86%和40.53%;小鼠热板法试验也使痛哿明显提高,白芷煎剂4g(生药)/kg灌胃,对二甲苯所鼓小鼠耳部炎症也有明显抑制作用。
升麻:现代药理研究表明主要有:
①抗菌作用:升麻在试管内能抑制结核杆菌的生长。
②抗炎作用:北升麻对大鼠角叉等胶或右旋糖酐所致脚肿胀均有消炎作用,对乳酸或醋酸引起的肝门溃疡,有使其缩小面积的趋势。
③具升高白细胞,抑制血小板的聚集及释放功能。
冰片:龙脑冰片含右旋龙脑,又含葎草烯、β-榄香烯、石竹烯等倍半萜,以及齐墩果酸、麦珠子酸、积雪草酸、龙脑香醇、古柯二醇等三萜化合物。艾片含左旋龙脑;机制冰片为消旋混合龙脑。药理作用:冰片中的主要成分龙脑、异龙脑均有耐缺氧的作用;龙脑、异龙脑有镇静作用;冰片局部应用对感觉神经有轻微刺激,有一定的止痛及温和的防腐作用;经肠系膜吸收迅速,给药5分钟即可通过血脑屏障,且在脑蓄积时间长,量也相当高,此为冰片的芳香开窍作用提供了初步试验依据;较高浓度(0.5%)对葡输球菌、链球菌、肺炎双球茵、大肠杆菌及部分致病性皮肤真菌等有抑制作用。
本发明采用经皮给药,具有可绕过肝脏首过效应及胃肠道干扰,生物利用度高,较易维持稳定的血液浓度,能延长药物作用时间,减少用药频率,降低药物用量,而且给药方便,可随时终止给药等独特的优点。
药理试验
(一)材料
1.动物
昆明种小白鼠体重16--22g,雌雄各半;
Wistar大白鼠体重120--180g,雌雄各半;
2.药物与试剂
本发明高、中、低浓度三种规格,分别为临床用药(临床每人每日用生药量为3.62g)的2倍,1倍,0.5倍,由山东中医药大学中药制剂试验室室提供。
扶他林(双氯芬酸二乙胺乳胶剂),北京诺华制药有限公司, 国药准字H19990291。
冰醋酸 济南试剂厂批号:2000731;
二甲苯 济南化学试剂厂批号:2000527;
试剂:大鼠细胞因子试剂盒,购自上海西唐生物科技有限公司专业生产,批号:20081024。
(二)方法与结果
1.抗炎作用研究
1.1对二甲苯诱发小鼠耳肿胀的影响
取18-22g雌雄性小鼠50只,随机分为5组,每组10只。设空白组,本发明高、中、低剂量组,扶他林组。试验当日各组小鼠双耳涂相应药物1次,面积3cm2/左右,30min后各组以蒸馏水棉球擦洗去药液,然后用干棉球擦净,给小鼠右耳涂二甲苯0.05ml/只致肿,左耳不涂作对照。2h后将小鼠断颈处死,用8mm直径打孔器在每只动物双耳相同部位打下圆耳片,置于电子分析天平上称重。以左右耳片重之差为肿胀度,以重量差值/左耳重量(%)为肿胀率,并求出肿胀抑制率。
表1 对二甲苯致小鼠耳廓肿胀的影响(X±S)
注:各组与空白组比较,采用t检验。
本发明的高、中、低剂量组,扶他林组与空白组比较有非常显著的差异。这说明本发明三个剂量组与扶他林组都具有抗二甲苯所致小鼠耳廓肿胀作用,其中本发明高剂量组为最佳。
蛋清诱发大鼠足肿胀的影响
取Wistar大白鼠50只,雌雄各半,按体重随机分为空白组,本发明高、中、低剂量组,扶他林组,每组10只。试验当日首先用自制容量测定装置测定各组大鼠右足正常体积(ml),然后给各组大鼠右后足涂相应药物(药量0.5ml·10g-1),涂药后贴片覆盖30min后,于右后足皮下注射100%新鲜鸡蛋清0.lml/只,测定注射后3Omin、lh、2h、4h的右后足体积。致炎前后右后足体积的变化值与初始体积的比值为肿胀率。
表2 本发明对蛋清致炎大鼠足趾肿胀的影响(X±S)
注:与空白组比较采用t检验 *P<0.05 **P<0.01
结果显示:本发明组于致炎后0.5~6h,均有明显的抗大鼠蛋清性足肿胀作用,分别与空白对照组比,P<0.01或P<0.05,见表2。
镇痛作用研究
2.1对热板刺激诱发小鼠疼痛的影响
将♀小鼠分别置于55±0.5℃的热板上,以舔后足所需时间(s)为痛阈值。先挑选出2次平均痛阈值在5~30s内的小鼠50只,随机等分5组,然后于小鼠四足踝关节至足跖皮肤涂药物0.5ml·10g-1,涂药后贴片覆盖。末次涂药后0.5、1、1.5和2h,同法测定痛阈值(如60s仍无疼痛反应,取出小鼠,以免烫伤,其痛阈值按60s计)。
表3 本发明对雌性小鼠热板法致痛的影响(n=10 X±SD)
注:与空白组比较,采用t检验,*P<0.05 **P<0.01
与扶他林组比较,采用t检验,△P<0.05 △△P<0.01
与给药前比较,采用t检验,##P<0.01
结果显示:在所观察的时相点内,扶他林, 本发明能显著提高小鼠对热板致痛的痛阈值,与空白对照组比,P<0.01或P<0.05, 见表3。
对醋酸诱发小鼠疼痛的影响
取小鼠50只,分5组,皮肤脱毛, 涂药物0.5ml·10g-1, 涂药后贴片覆盖涂药0.5h后, 0.6%醋酸0.2ml/只致痛。观察并记录20min内小鼠扭体反应的潜伏期和扭体反应次数。
表4 本发明对冰醋酸所致小鼠疼痛的影响(X±SD)
注:与空白组比较,采用成组t检验,*P<0.05 **P<0.01;与扶他林组比较,采用成组t检验,△P>0.05。
结果显示:扶他林, 本发明对小鼠醋酸性扭体反应的次数均明显的减少,潜伏期显著延长,与对照组比,P<0.01。
肉芽肿炎性细胞因子的影响
阳证疮疡动物模型的建立:大鼠棉球肉芽试验法 100~150 Wistar大白鼠60只,随机分为5组,每组12只,给药前在无菌条件下于大鼠两侧腹股沟皮下分别植入25 mg消毒干棉球,造成炎性动物模型。造模后分5组(空白组,本发明高、中、低剂量组,扶他林组),每天涂药物0.5ml·10g-1, 涂药后贴片覆盖,第8天处死大鼠并剥离出肉芽组织分别观察8天后处死大鼠并称重,剥离出肉芽肿球,观察肉芽球的颜色,重量及病理切片变化并取出等量肉芽组织,组织匀浆,分离得血清,于-20℃保存待测。测试前将标本置室温复融,混匀后40℃, 3OOOrpm离心5min,取上清液供测试用。以放射免疫分析法检测各组细胞因子并记录其数值,剩余部分于60℃烘干至恒重,计算各鼠每百克体重之肉芽肿重量,作统计分析。
表5 肉芽球的颜色,重量及病理切片变化
本发明高、中、低剂量组,扶他林组与空白组比较有非常显著的差异,P<0.05,本发明三个剂量组与扶他林组都具有减轻肉芽肿组织反应作用。
表6 用药后大鼠肉芽组织细胞因子水平的变化(ng/mL,x±s)
注:各组与空白组比较,采用t检验,P<0.01。
本发明高、中、低剂量组,扶他林组与空白组比较有非常显著的差异,P<0.05,说明本发明三个剂量组与扶他林组都具有减少肉芽肿促炎性细胞因子作用,其中本发明大剂量组为最佳,本发明三个剂量组与扶他林组具有增加肉芽肿抑制炎性细胞因子作用,其中本发明大剂量组为最佳。
体外抑菌试验
取已灭菌滤纸圆片,浸泡于本发明三种不同浓度提取液中,待干备用。培养基采用M-H琼脂和加入绵羊血5%琼脂,药物敏感试验采用K-B纸片扩散法。即将含有一定量本发明提取液的纸片,平贴于已接种被检菌的M-H琼脂平板上。纸片中的抗菌药物溶解于培养基内,并向四周扩散,抑制细菌生长从而出现抑菌环,观察抑菌环的大小。
表7 抑菌环的情况
这说明本发明高、中、低剂量三组均有抑制细菌生长作用,高剂量组抑制明显,P<0.05有统计学意义。
统计学方法
各项数据均以均值±标准差(±S)表示。计量资料采用t检验,计数资料X2采用检验, P<0.05为差异有显著性。所有资料采用SPSS17.0统计软件处理。
毒理研究
(一)皮肤刺激性试验
取家兔8只,给药部位为背部皮肤,药前24h用手术剪刀剪毛后,以8%硫化钠脱毛,面积约7cm×10cm,随机将动物背部脱毛区分为完整皮肤对照区和完整皮肤给药区,每个区域面积为3.5cm×10cm,给药区贴敷受试药物、对照区贴敷基质,药物与皮肤接触24h后用清水轻轻洗去药膏及基质,观察皮肤反应情况,记录去除药物即刻、12h、24h、48h、72h皮肤反应情况,参照表8、表9标准,观察有无红斑、水肿、隆起、焦痂形成等,对每只动物的皮肤反应强度评分,观察药物对皮肤刺激情况。
表8 皮肤反应评分标准
反应平均值=(红斑形成总分+水肿形成总分)/合计动物数
表9 皮肤刺激强度评价
反应平均值=(红斑形成总分+水肿形成总分)/合计动物数。
动物在去除受试药后即刻及72h内发现未发现皮肤有任何刺激性症状。动物精神状态、活动、呼吸、摄食量、体重、外观、大小便形状及颜色、背毛、肤色等皆未见异常,鼻、眼、口腔亦无异常分泌物。
取家兔8只,药前24h用手术剪刀剪毛后,以8%硫化钠脱毛,面积约7.5cm×10cm,随机将动物背部脱毛区分为皮肤对照区、皮肤给药区2个区域,每个区域面积为3.5cm×10cm。给药区贴敷受试药物、对照区贴敷基质,每天一次,连续给药10天,停药后继续观察2天。每日密切观察皮肤反应情况,观察有无红斑、水肿、隆起、焦痂形成等,参照标准同急性刺激试验,对每只动物的皮肤反应强度进行评分,试验结果见表10。
动物用药部位皮肤颜色正常,药后未出现发红,也未见任何其它刺激症状,所有动物精神状态、活动、呼吸、摄食量、体重、外观、大、小便形状及颜色、背毛、肤色等皆未见异常,鼻、眼、口腔亦无异常分泌物。
表10连续给药对家兔皮肤刺激情况
结论:本发明对家兔完整皮肤无刺激性。
(二)皮肤过敏性试验
1.试验动物分组
第一组为基质组(阴性对照组),第二组为本发明组(药物组),第三组为2,4-二硝基氯苯组(阳性对照药);豚鼠,雌雄各半,体重240—280g,每组6只,每只动物单笼饲养。
阳性对照药
2,4-二硝基氯苯:中国上海试剂一厂生产,批号:08-08-01,用吐温-80乳化后稀释成1%的致敏浓度和0.1%的激发浓度。
试验方法
给药前18h豚鼠用10%硫化钠在脊柱两侧脱毛,面积约3cm×3cm,第一组、第二组分别贴敷基质、本发明,第三组涂0.5ml1%2.4-二硝基氯苯,并用油纸覆后以双层纱布固定,使药物与皮肤充分接触。第2天后用温水将药膏或药液轻轻洗去,试验第7与第14天以同样方法重复给药,第28天用同样的方法激发给药,2.4-二硝基氯苯为0.1%的激发浓度。6h后将受试药物用清水洗去,并立即观察皮肤过敏反应情况,然后于24h、48h、72h再次观察皮肤过敏反应情况,观察有无红斑、水肿,动物站立情况、是否有哮喘、休克等,按照表11标准进行评价。
表11 致敏率分类标准
4.试验结果
本发明在激发给药6h、24h、72h皆未见水肿、红斑等过敏性症状,2.4-二硝基氯苯有轻度和中度红斑,无水肿,并有动物出现哮喘、旋转等,致敏率为100%。试验结果(见表12):
表12 对豚鼠皮肤过敏的影响
结论:本发明对豚鼠皮肤未见皮肤过敏反应。
(三)急性毒性试验
1.组成
本发明:生芙蓉叶、连翘、生大黄、生南星、白芷、生升麻、冰片
本发明基质组(以下简称基质组):为不含任何药物的本发明基质组成,面积相同。
试验方法
给药前24h用8%硫化钠脱毛,面积约8cm×5cm,选用皮肤未损伤的豚鼠30只,体重280--320g,随机分成基质组、本发明组,共2组,每组10只,雌雄各半。分别在脱毛区贴基质、受试药,每次8cm×5cm,1次/天,并密切观察皮肤反应情况。次日,去除巴布膏,并用清水洗去附着物。所有动物单笼饲养,然后连续观察14天,每天观察豚鼠活动情况、摄食情况、呼吸、精神状态、体重、大、小便情况及背毛、肤色等。
试验结果
给药后所有动物均无异常发现,动物精神状态、活动、呼吸、摄食量、体重、外观、大、小便形状及颜色、被毛、肤色等皆未见异常,鼻、眼、口腔亦无异常分泌物,亦未见动物有死亡。大剂量组及小剂量组给药区部位个别动物皮肤颜色稍微发红,但未见水肿、红斑等刺激性反应,也未见色素沉积。动物体重变化和皮肤变化情况(见表13)。
表13 本发明对完整皮肤刺激的影响
临床每人每日用生药量为3.62g。大剂量组本发明豚鼠用量(含生药量)为:1.504g生药/kg,给药量相当于临床60kg人每千克体重用量的25倍,说明本品低毒、安全。
结论:豚鼠完整皮肤,未出现明显的毒性反应,对完整皮肤未见明显的刺激性。该剂量约为临床给药量的25倍,说明本品低毒、安全。
具体实施方式
下面结合实施例对本发明作进一步的说明。
实施例1
(1)药物的前处理:生芙蓉叶、连翘、生大黄、生南星、白芷、升麻、冰片,按《中国药典》一部相应饮片下的处理方法处理,备用;
(2)取生芙蓉叶1000g、连翘1000g、生大黄1000g、生南星1000g、白芷1000g、升麻1000g粉碎过6号筛,备用;
(3)将冰片50g加于香油中使其溶解,再加入上述药粉、凡士林及1%~6%的氮酮,充分混合制成棕褐色软膏,备用;所述凡士林、香油、药粉的质量比为3:9:12;
(4)将软膏摊涂于贴片上,即制备成治疗阳证疮疡的中药贴片。(可根据创面的大小,摊涂成不同的剂量,生药粉含量分别为:1.5g,3g, 6g。)
实施例2
(1)药物的前处理:生芙蓉叶、连翘、生大黄、生南星、白芷、升麻、冰片,按《中国药典》一部相应饮片下的处理方法处理,备用;
(2)取生芙蓉叶800g、连翘1200g、生大黄800g、生南星1200g、白芷800g、升麻1200g粉碎过6号筛,备用;
(3)将冰片60g加于香油中使其溶解,再加入上述药粉、凡士林及1%~6%的氮酮,充分混合制成棕褐色软膏,备用;所述凡士林、香油、药粉的质量比为3:9:12;
(4)将软膏摊涂于贴片上,即制备成治疗阳证疮疡的中药贴片。(可根据创面的大小,摊涂成不同的剂量,生药粉含量分别为:1.5g,3g, 6g。)
实施例3
(1)药物的前处理:生芙蓉叶、连翘、生大黄、生南星、白芷、升麻、冰片,按《中国药典》一部相应饮片下的处理方法处理,备用;
(2)取生芙蓉叶1200g、连翘800g、生大黄1200g、生南星800g、白芷1200g、升麻800g粉碎过6号筛,备用;
(3)将冰片40g加于香油中使其溶解,再加入上述药粉、凡士林及1%~6%的氮酮,充分混合制成棕褐色软膏,备用;所述凡士林、香油、药粉的质量比为3:9:12;
(4)将软膏摊涂于贴片上,即制备成治疗阳证疮疡的中药贴片。(可根据创面的大小,摊涂成不同的剂量,生药粉含量分别为:1.5g,3g, 6g)。
Claims (1)
1.一种治疗阳证疮疡的中药贴片的制备方法,其特征在于,包括以下步骤:
(1)药物的前处理:生芙蓉叶、连翘、生大黄、生南星、白芷、升麻、冰片,按药典一部相应饮片下的处理方法处理,备用;
(2)取生芙蓉叶800-1200、连翘800-1200、生大黄800-1200、生南星800-1200、白芷800-1200、升麻800-1200粉碎过6号筛,备用;
(3)将冰片40-60份加于香油中使其溶解,再加入上述药粉、凡士林及1%~6%的氮酮,充分混合制成棕褐色软膏,备用;所述凡士林、香油、药粉的质量比为3:9:12;
(4)将软膏摊涂于贴片上,即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410230329.7A CN103977187A (zh) | 2014-05-28 | 2014-05-28 | 一种治疗阳证疮疡的中药贴片的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410230329.7A CN103977187A (zh) | 2014-05-28 | 2014-05-28 | 一种治疗阳证疮疡的中药贴片的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103977187A true CN103977187A (zh) | 2014-08-13 |
Family
ID=51269514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410230329.7A Pending CN103977187A (zh) | 2014-05-28 | 2014-05-28 | 一种治疗阳证疮疡的中药贴片的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103977187A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102337A (zh) * | 1993-11-05 | 1995-05-10 | 郑州铁路分局医院 | 烧伤创疡膏 |
| EP1506782A1 (en) * | 2003-08-11 | 2005-02-16 | I-Hung Chu | Vapor fraction from seeds of glycine max (L.) merr. and composition thereof |
-
2014
- 2014-05-28 CN CN201410230329.7A patent/CN103977187A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102337A (zh) * | 1993-11-05 | 1995-05-10 | 郑州铁路分局医院 | 烧伤创疡膏 |
| EP1506782A1 (en) * | 2003-08-11 | 2005-02-16 | I-Hung Chu | Vapor fraction from seeds of glycine max (L.) merr. and composition thereof |
Non-Patent Citations (2)
| Title |
|---|
| 刘学华: "痈疡消剂的组方配伍特点", 《山东中医学院学报》 * |
| 夏兆芳等: "消炎透皮贴对肉芽肿炎性细胞因子的作用研究", 《中国医学创新》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bedi et al. | Herbal therapy in dermatology | |
| WO2017101790A1 (zh) | 用于治疗皮肤瘙痒病症的药物组合物及其应用 | |
| US20160051595A1 (en) | External-use medicament for cleaning and care of the ovaries, vagina and vulva | |
| CN104983891A (zh) | 用于治疗伤口的中药方剂及基于该中药方剂的中药油敷料的制备方法 | |
| CN110664858A (zh) | 一种用于皮肤的青蒿提取物组合物、产品及其应用 | |
| CN113797250B (zh) | 一种外用中药组合物及制备方法和应用 | |
| CN101780205B (zh) | 用于治疗奶牛乳房炎的中药复方透皮贴剂及制备方法 | |
| CN102274355B (zh) | 一种治疗猪口蹄疫病的外用药物 | |
| CN105943666B (zh) | 一种用于婴幼儿敏感肌肤护理的组合物及其制备方法 | |
| CN101829182B (zh) | 一种治疗前列腺疾病的药物 | |
| CN104523853A (zh) | 一种复方紫草油外用制剂及其制备方法 | |
| CN103251691B (zh) | 治疗奶牛乳房炎的中药方剂及其提取物和制剂 | |
| CN104666594B (zh) | 一种治疗足癣用灸条及其制备方法 | |
| Azahar et al. | Therapeutic Evaluation of a Topical Unani Formulation, Tila-i Muhāsā in Buthūr Labaniyya (Acne Vulgaris): A Randomized, Controlled Clinical Study | |
| CN110038056A (zh) | 一种治疗宠物肢体炎性肿胀的复方五倍子软膏及其制备方法 | |
| CN103977187A (zh) | 一种治疗阳证疮疡的中药贴片的制备方法 | |
| CN103251713B (zh) | 一种用于畜禽皮癣的中药制剂 | |
| CN103977186A (zh) | 一种治疗阳证疮疡的中药贴片 | |
| CN102225113A (zh) | 一种用于治疗动物皮肤病的中药制剂 | |
| Viquar | Detoxification of the therapeutically essential drug Aelwa (Aloe vera (L.) Burm. f.) using a modified traditional method | |
| WO2017181245A1 (en) | Method of treating inflammation and promoting wound healing | |
| CN113181336A (zh) | 一种治疗妇科疾病的中药组合物、制剂及其制备方法和应用 | |
| CN113633717B (zh) | 鼻腔护理电子雾化液组合物、其用途及所得的护理产品 | |
| CN109908304A (zh) | 中药组合物及其用途、外用中药制剂及其制备方法 | |
| RU2782695C1 (ru) | Состав для наружного применения "септисол" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140813 |
|
| RJ01 | Rejection of invention patent application after publication |